Thc Therapeutics Inc Financials
This page shows Thc Therapeutics Inc (THCT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
We are recalculating Thc Therapeutics Inc's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.
Key Financial Metrics
Earnings & Revenue
Thc Therapeutics Inc generated $0 in revenue in fiscal year 2024.
Cash & Balance Sheet
Thc Therapeutics Inc held $35 in cash against $0 in long-term debt as of fiscal year 2024.
Thc Therapeutics Inc had 40M shares outstanding in fiscal year 2024. This represents an increase of 22.8% from the prior year.
Margins & Returns
Capital Allocation
THCT Income Statement
| Metric | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $0 | $0 | $0 | N/A | $0 | $0 | $0 |
| Cost of Revenue | N/A | $0 | $0 | $0 | N/A | $0 | $0 | $0 |
| Gross Profit | N/A | $0 | $0 | $0 | N/A | $0 | $0 | $0 |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | N/A | $9K+24.2% | $7K+465.9% | $1K | N/A | $3K-94.1% | $58K+644.6% | $8K |
| Operating Income | N/A | N/A | N/A | -$55K | N/A | -$58K | N/A | -$108K |
| Interest Expense | N/A | $18K-6.8% | $20K+1.5% | $19K | N/A | $19K-4.2% | $20K-0.3% | $20K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
THCT Balance Sheet
| Metric | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $11K-9.9% | $12K-20.3% | $15K+27.0% | $12K-10.2% | $13K-2.7% | $13K-42.0% | $23K-59.3% | $57K |
| Current Assets | $35-95.9% | $849-75.8% | $4K+35010.0% | $10-99.0% | $980-0.5% | $985-90.5% | $10K-76.3% | $44K |
| Cash & Equivalents | $35-95.9% | $849-75.8% | $4K+35010.0% | $100.0% | $10-33.3% | $15-99.8% | $9K+148.1% | $4K |
| Inventory | N/A | N/A | N/A | $0 | $0 | $0 | $0 | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $3.8M+7.9% | $3.5M-9.7% | $3.9M+15.5% | $3.4M+1.8% | $3.3M+1.0% | $3.3M-3.1% | $3.4M-35.7% | $5.3M |
| Current Liabilities | $3.8M+11.1% | $3.4M-9.9% | $3.8M+16.0% | $3.3M-1.2% | $3.3M+4.2% | $3.2M-3.2% | $3.3M-36.4% | $5.2M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$3.8M-8.0% | -$3.5M+9.6% | -$3.9M-15.5% | -$3.4M-1.9% | -$3.3M-1.0% | -$3.3M+2.8% | -$3.4M+35.5% | -$5.2M |
| Retained Earnings | -$39.2M-0.7% | -$39.0M+0.3% | -$39.1M-1.5% | -$38.5M-0.2% | -$38.4M-0.1% | -$38.4M+0.2% | -$38.5M+4.2% | -$40.2M |
THCT Cash Flow Statement
| Metric | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$814 | N/A | -$45K-16676.2% | -$269-472.3% | -$47+97.8% | -$2K+96.5% | -$62K-187.3% | -$21K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | $0 | $0 | $0 | $0 | $0 | $0 |
| Financing Cash Flow | $0 | N/A | $49K+17977.7% | $269+540.5% | $42+100.6% | -$7K-109.9% | $67K+167.8% | $25K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | $0 | $0 | N/A | N/A |
THCT Financial Ratios
| Metric | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | 0.000.0 | 0.000.0 | 0.000.0 | 0.000.0 | 0.000.0 | 0.000.0 | 0.000.0 | 0.01 |
| Debt-to-Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$3.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Thc Therapeutics Inc's annual revenue?
Thc Therapeutics Inc (THCT) reported $0 in total revenue for fiscal year 2024. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
What are Thc Therapeutics Inc's total assets?
Thc Therapeutics Inc (THCT) had $11K in total assets as of fiscal year 2024, including both current and long-term assets.
What is Thc Therapeutics Inc's current ratio?
Thc Therapeutics Inc (THCT) had a current ratio of 0.00 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
Why is Thc Therapeutics Inc's debt-to-equity ratio negative or not reported?
Thc Therapeutics Inc (THCT) has negative shareholder equity of -$3.8M as of fiscal year 2024, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.